SOC Analysts and Threat Hunters Warn: Edge Devices May Be a Security Blind Spot CXO Digitalpulse
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
